La start-up lausannoise Endoart lève 14 millions de francs suisses
Des tests cliniques pourront désormais être effectués sur les implants vasculaires d’Endoart.
Publicité
levée de fonds
Publicité
Publicité
- ABB LTD N45.051.65%
- ALCON N79.561.61%
- RICHEMONT N144.81.15%
- GEBERIT N585.81.21%
- GIVAUDAN N39990.35%
- HOLCIM N94.021.27%
- KUEHNE+NAGEL INT N183.80.58%
- LOGITECH N65.643.6%
- LONZA N571.2-1.14%
- NESTLE N87.06-1.24%
- NOVARTIS N91.11-0.77%
- PARTNERS GROUP N1098.52.38%
- ROCHE GS259.9-2.37%
- SIKA N206.31.03%
- SONOVA HOLDING AG253.50.52%
- SWISS LIFE HOLDING AG N839.8-0.36%
- SWISS RE N149.15-1.68%
- SWISSCOM N540-1.01%
- UBS GROUP N25.771.34%
- ZURICH INSURANCE N583-1.72%
- ABB LTD N45.051.65%
- ALCON N79.561.61%
- RICHEMONT N144.81.15%
- GEBERIT N585.81.21%
- GIVAUDAN N39990.35%
- HOLCIM N94.021.27%
- KUEHNE+NAGEL INT N183.80.58%
- LOGITECH N65.643.6%
- LONZA N571.2-1.14%
- NESTLE N87.06-1.24%
- NOVARTIS N91.11-0.77%
- PARTNERS GROUP N1098.52.38%
- ROCHE GS259.9-2.37%
- SIKA N206.31.03%
- SONOVA HOLDING AG253.50.52%
- SWISS LIFE HOLDING AG N839.8-0.36%
- SWISS RE N149.15-1.68%
- SWISSCOM N540-1.01%
- UBS GROUP N25.771.34%
- ZURICH INSURANCE N583-1.72%